It seems there are no more sellers just a few doing naked shorts. Will be interesting once the inevitable short squeeze starts and they scramble to cover....
BTW I read the comments on the fools' page. I can't believe how amateur they are; they will be hurting.
It seems Bio Tech is out in the moment and the question looms 'Will REGN ever hit 400?'.
There are soo many positive developments within the biotech sector that once we get behind the holidays the buying will continue, and I believe REGN will at one point hit 400, maybe not in January but next year.
Right now REGN is almost at its 52 week low. Reviewing a yearly chart REGN never spend much time closed to the 200 MA. Therefore I would expect a turning point sometimes pretty soon.
BB&T Corp target raised to $43 at Compass Point
Compass Point raises their BBT tgt to $43 from $40. The firm says, in the near-term, there will be some headwinds in the fourth quarter due to "flattish" loan growth and a 10 bp decline in NIM. The relatively flat loan balances are partly due to seasonal items and the decline in NIM is due to the sale of a $500M loan portfolio and Colonial run-off (both of which do not effect core NIM). They say while management has been talking about expense management for some time, this is the first comments the company has made citing specific efficiency targets
some thoughts about possible target prices:
The merger will complete sometimes in spring. PacWest had a previous high of roughly 60. Together with CSE there should be value add, and hopefully we can take out the high of 60. That would mean a roughly 30 % premium to the current stock price of 40.
Translating this logic to the CSE price movement wold imply a target price of 18, which is not too far of where CSE traded prior recession.
Sentiment: Strong Buy
21k shares still represent roughly $ 6 Mill; I haven't looked at the cost of the option, but I don't think it's a co-incident that REGN was pinned to 280
Check out these companies and you'll see the potential of CTIX
it's an exciting opportunity. we've got allergies, cholesterol, diabetic macular,
and we haveeylea, a lot happening. we have an enormous talent in the labs and he and his
research team have come up with different opportunities for us, we've got 13 different
products in clinical development and a whole bunch more moving forward which we haven't
talked with you about. excellent. well, i know we're going to in the future. go and listen to this
conference call. you will know why i am still excited even at $300 a share. stay with cramer
Video Transcript -Regeneron CEO: Moreopportunities togrowEylea - CNBC
a group of diseases that are allergic diseases. you get asthma, eczema, nasal poll -- we
hope it's an opportunity, still investigational, a lot of risk, but we're very excited about it.
your senior vice president used the phrase, it brought chills to me. we have seen a
stabilization in your opponent, the share. was it 65, down to 48, why aren't you taking them -
- those bad boys down to 40? why can't -- suddenly your drug, giving their drug away? well,
no, their drug is a lot er and it's used awful label and there are structural changes coming in
compound legislation. meaning that the government may not really like that kind of split up
of the vial. regeneron's view is we're in favor of choice. while patients should have lots of
choices which is good to have a choice, it's good to have a choice, we think there should
only be one quality standard. lots of drugs but only one quality standard. we think that's
what the new law may accomplish and we're looking forward to that. okay. but we have seen
instances where you break open the vial where there's been horrible -- there's been
deaths. well, there's been deaths when people have injected drugs that have compounded.
there has been blindness. this is why we need one quality standard. we need the fda to
regulate this and that's what i think the new compounding legislation if it gets passed will
actually do and it'll make things safer. now, just circle back, it's pertinent now. the diabetic,
you're saying that's ready. that's one of the things -- you're saying they're just waiting.
you're ready to go the moment that thing -- we are ready to go but we still have to go
through the approval process. we've submitted -- what are those people taking right now?
they're using lucentis, it's ahead of us. there's some opportunity out there for people to get
treated. we think our drug could be good, but we have to go through the review process
with the fda.